一项评估Selnoflast在降低有主要不良心脏事件风险的动脉粥样硬化参与者血管炎症方面的疗效、安全性、药效学(PD)和药代动力学(PK)的研究 (RIVULET)
一项关于Selnoflast在降低具有主要不良心脏事件风险的动脉粥样硬化患者血管炎症方面的疗效、安全性、药效学和药代动力学的IIa期、多中心、随机、双盲、安慰剂对照研究
The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Reference Study ID Number: GC46102 https://forpatients.roche.com/
- 电话号码:888-662-6728
- 邮箱:global-roche-genentech-trials@gene.com
研究联系人备份
- 姓名:Fastest response: use the inquiry form. No email attachments https://www.gene.com/contact-us/submit-medical-inquiry
学习地点
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8W 3K5
- 招聘中
- Cardio Health Clinical Trials
-
-
-
-
California
-
Beverly Hills、California、美国、90210
- 招聘中
- Cardiovascular Research Foundation of Southern California
-
Beverly Hills、California、美国、90211
- 招聘中
- National Heart Institute
-
Irvine、California、美国、92604
- 招聘中
- Amnova Clinical Research
-
Los Angeles、California、美国、90095
- 招聘中
- UCLA Health System - UCLA Cardiovascular Center
-
Santa Rosa、California、美国、95405
- 招聘中
- NorthBay Clinical Research
-
West Hills、California、美国、91307
- 招聘中
- Alliance Clinical West Hills (Focus Clinical Research)
-
-
Connecticut
-
New Haven、Connecticut、美国、06520-8040
- 招聘中
- Yale University School of Medicine Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital
-
-
Florida
-
Miami Lakes、Florida、美国、33014
- 招聘中
- Inpatient Research Clinic (Las Palmas Medical Research Center)
-
-
Indiana
-
Hammond、Indiana、美国、46324
- 招聘中
- Asha Clinical Research-Munster,Llc
-
-
Michigan
-
Bloomfield Hills、Michigan、美国、48304
- 招聘中
- Profound Research LLC at Cardiology and Vascular Associates - CAVA
-
Farmington Hills、Michigan、美国、48334
- 招聘中
- Profound Research LLC at Millenium Cardiology
-
Flint、Michigan、美国、48504
- 招聘中
- Ahmed Arif Medical Research Center (AA MRC LLC )
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- 招聘中
- University of Minnesota
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University, School of Medicine
-
-
Nebraska
-
Omaha、Nebraska、美国、69198-4130
- 招聘中
- University of Nebraska Medical Center
-
-
New York
-
North Massapequa、New York、美国、11758-1802
- 招聘中
- DiGiovanna Inst for Med Ed&Res
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599
- 招聘中
- UNC Heart & Vascular
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15243
- 招聘中
- Preferred Primary Care Physicians, Inc
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Vanderbilt University School of Medicine (VUSM) - Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC)
-
-
Texas
-
Dallas、Texas、美国、75235
- 招聘中
- Southwest Family Medicine Associates
-
Houston、Texas、美国、77002
- 招聘中
- East Texas Cardiology PA
-
Houston、Texas、美国、77070
- 招聘中
- Cardiovascular Specialists of Willowbrook
-
San Antonio、Texas、美国、78229
- 招聘中
- UT Health San Antonio
-
-
Washington
-
Lynnwood、Washington、美国、98036
- 招聘中
- Eastside Research Associates, LLC dba Era Health Research
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Confirmed evidence of atherosclerosis
- Left or right carotid TBR ≥ 1.8 or aorta TBR ≥ 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan
- Stable treatment of atherosclerosis through the use of SOC medications or revascularization
- QT interval corrected through use of Fridericia's formula (QTcF) of ≤ 450 milliseconds (ms) in men and ≤ 470 ms in women by a single 12-lead electrocardiogram (ECG) recording
Exclusion Criteria:
- Individuals with Class III and IV heart failure
- Uncontrolled cardiac arrhythmia
- Uncontrolled hypertension
- Suspected or known immunocompromised state
- Planned procedure or surgery during the study and any major surgery within 90 days prior to screening Visit 1
- History of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
- Positive test results for hepatitis B (HBV) infection at screening
- Positive hepatitis C virus (HCV) antibody test at screening
- Positive human immunodeficiency virus (HIV) test at screening
- Estimated glomerular filtration rate <50 mL/min/1.73 m² as calculated through use of the Chronic Kidney Disease Epidemiology Collaboration equation, at the time of screening.
- Treatment with any live vaccine within 28 days prior to the first dose of study drug until the end of the study
- Treatment with other non-live vaccines within 14 days prior to the first dose of study drug until the end of the study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Selnoflast
Participants will receive selnoflast, orally (PO), twice a day (BID) for 12 weeks. |
Selnoflast will be administered as per the schedule specified in the respective arm.
其他名称:
|
|
安慰剂比较:Placebo
Participants will receive placebo, PO, BID for 12 weeks. |
Placebo will be administered as per the schedule specified in the respective arm. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in mdsTBR (Most-diseased Segment TBR [Target-to-background Ratio]) of Index Vessel From Baseline to Week 12 in Participants With Baseline Elevated hsCRP (≥ 2 milligrams per liter [mg/L])
大体时间:Baseline up to Week 12
|
hsCRP=high-sensitivity C-reactive protein. |
Baseline up to Week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
所有参与者(hsCRP < 2 mg/L 和 ≥ 2 mg/L)第12周时指数血管mdsTBR相对于基线的变化
大体时间:基线和第12周
|
基线和第12周
|
|
|
所有参与者(hsCRP < 2 mg/L 和 ≥ 2 mg/L)第12周时颈动脉 mdsTBR 相对于基线的变化
大体时间:基线和第12周
|
基线和第12周
|
|
|
基线hsCRP升高(≥2 mg/L)受试者第12周时颈动脉mdsTBR相对于基线的变化
大体时间:基线和第12周
|
基线和第12周
|
|
|
所有参与者(hsCRP < 2 mg/L 和 ≥ 2 mg/L)第12周时靶血管活性节段TBR及全血管TBR较基线的变化
大体时间:基线和第12周
|
基线和第12周
|
|
|
基线hsCRP升高(≥ 2 mg/L)的参与者第12周时靶血管活性节段TBR和整支靶血管TBR相对于基线的变化
大体时间:基线和第12周
|
基线和第12周
|
|
|
塞诺氟拉斯特在指定时间点的血浆浓度
大体时间:最长 12 周
|
最长 12 周
|
|
|
Number of Participants With Adverse Events (AEs) and Severity of AEs Determined According to the NCI CTCAE v5.0 Grading Scale
大体时间:Up to approximately 22 weeks
|
NCI CTCAE v5.0 = National Cancer Institute's Common Terminology Criteria for Adverse Events, Version 5.0. |
Up to approximately 22 weeks
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Genentech, Inc.
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.